Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19

Walid Hamouche, Malik Bisserier, Agnieszka Brojakowska, Abrisham Eskandari, Kenneth Fish, David A. Goukassian, Lahouaria Hadri

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

The first confirmed case of novel Coronavirus Disease 2019 (COVID-19) in the United States was reported on January 20, 2020. As of November 24, 2020, close to 12.2 million cases of COVID-19 was confirmed in the US, with over 255,958 deaths. The rapid transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), its unusual and divergent presentation has strengthened the status of COVID-19 as a major public health threat. In this review, we aim to 1- discuss the epidemiological data from various COVID-19 patient cohorts around the world and the USA as well the associated risk factors; 2- summarize the pathophysiology of SARS-CoV-2 infection and the underlying molecular mechanisms for the respiratory and cardiovascular manifestations; 3- highlight the potential treatments and vaccines as well as current clinical trials for COVID-19.

Original languageEnglish
Pages (from-to)72-85
Number of pages14
JournalJournal of Molecular and Cellular Cardiology
Volume153
DOIs
StatePublished - Apr 2021

Keywords

  • COVID-19
  • Clinical features
  • Physiopathology
  • Treatment

Fingerprint

Dive into the research topics of 'Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19'. Together they form a unique fingerprint.

Cite this